[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100276849":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":36,"responsibleParty":53,"collaborators":10,"id":56,"slug":10,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Third Affiliated Hospital, Sun Yat-Sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"retreatment",null,"1. Patients with HBV DNA \\> 2000 IU\u002Fml and ALT ≥ 5×ULN;\n2. Patients with HBV DNA \\> 2000 IU\u002Fml and 2×ULN \\\u003C ALT ≤ 5×ULN, but have clinical symptoms.\n\nIntervention: Patients of this group will receive Entecavir 0.5mg\u002Fd or Tenofovir 300mg\u002Fd again.",[13],"Drug: Entecavir or Tenofovir",{"label":15,"type":10,"description":16,"interventionNames":10},"non-retreatment","1. Patients with HBV DNA ≤ 2000 IU\u002Fml;\n2. Patients with HBV DNA \\> 2000 IU\u002Fml and ALT ≤ 2×ULN;\n3. Patients with HBV DNA \\> 2000 IU\u002Fml and 2×ULN \\\u003C ALT ≤ 5×ULN, but have no clinical symptoms.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","Entecavir or Tenofovir","Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg\u002Fd or Tenofovir 300mg\u002Fd) again",[9],[24],{"name":25,"affiliation":5,"role":26},"Liang Peng, Doctor","PRINCIPAL_INVESTIGATOR",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Wenxiong Xu, Master","CONTACT","+8613760783281","xwx1983@163.com",{"name":25,"role":30,"phone":34,"phoneExt":10,"email":35},"+8613533978874","pzp33@hotmail.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"The Third Affiliated Hospital of Sun Yat-sen University","RECRUITING","Guangzhou","Guangdong","510630","China","CN",{"type":46,"coordinates":47},"Point",[48,49],113.25,23.11667,{"lat":49,"lon":48},[52],{"name":25,"role":30,"phone":34,"phoneExt":10,"email":35},{"type":26,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Liang Peng","Associated Professor","100276849",false,"NCT02883647","Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b","Clinical Investigation About Therapeutic Effects and Long-term Follow-up After Ending Anti-hepatitis B Virus Therapy With Nucleos(t)Ide Analogs in Patients With Chronic Hepatitis b","Inclusion Criteria:\n\n1. Patients received anti-HBV therapy with nucleos(t)ide analogs.\n2. Last anti-HBV therapy should continue for at least 2 years.\n3. For HBeAg positive patients, HBV DNA should keep negative for at least 1 year after HBeAg seroconversion before the therapy ending; for HBeAg negative patients, HBV DNA should keep negative for at least 2 years before the therapy ending.\n\nExclusion Criteria:\n\n1. Liver cirrhosis, HCC;\n2. Patients with other factors causing active liver diseases;\n3. Pregnancy or lactation;\n4. Patients with HIV infection or congenital immune deficiency diseases;\n5. Patients with severe diabetes, autoimmune diseases, other important organ dysfunctions and other serious complications.","ALL","18 Years","65 Years",{"count":66,"type":67},100,"ESTIMATED","OBSERVATIONAL","The study is to observe the therapeutic effects and long-term follow-up after ending anti-HBV therapy with nucleos(t)ide analogs in patients with chronic hepatitis b.",[71],"Chronic Hepatitis b",[73],"chronic hepatitis b, nucleos(t)ide analog","2024-11-26",{"date":76,"type":77},"2024-11-29","ACTUAL",{"date":79,"type":10},"2014-01-01",{"date":81,"type":67},"2024-12-31",{"name":5,"class":6},1]